---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-048579"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:57:06.447990+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma Q1 net loss $3.8M; positive QRX003 data and patent expansion

## Summary
- Cash of $11.6M at March 31, 2025; expected to fund operations into Q1 2026.
- Net loss of $3.8M for Q1 2025, versus $2.3M in Q1 2024.
- QRX003 showed reversal of clinical benefits upon discontinuation, confirming mechanism of action.
- Patent applications filed for topical rapamycin and novel QRX003 formulations, extending IP to 2045.
- FDA-cleared whole-body QRX003 study at Northwestern University for 8-12 Netherton patients.

## SEC filing metadata
- accession: 0001104659-25-048579
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/0001104659-25-048579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/tm2515088d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-048579
- JSON: https://secwatch.observer/filing/0001104659-25-048579.json
- Plain text: https://secwatch.observer/filing/0001104659-25-048579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.